News >

FDA Places Partial Hold on Cervical Cancer Trial of AIM2CERV

Kristi Rosa
Published: Thursday, Jan 24, 2019

Kenneth A. Berlin

Kenneth A. Berlin

The FDA has placed a partial clinical hold on the phase III AIM2CERV trial (NCT02853604) evaluating the use of axalimogene filolisbac (AXAL) in patients with high-risk locally advanced cervical cancer, according to Advaxis, Inc., the developer of the investigational immunotherapy agent.1



  1. Advaxis’ Phase 3 AIM2CERV Study Placed on Partial Clinical Hold by FDA Related to CMC Requests [news release]. Advaxis; January 23, 2019. Accessed January 24, 2019.
  2. Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer (AIM2CERV). website. Published August 3, 2016. Updated April 12, 2018. Accessed January 24, 2019.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication